Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NBIP-01435 in Adults With Classic Congenital Adrenal Hyperplasia
NCT07850739Phase 2Not yet recruiting
- Sponsor
- Neurocrine Biosciences
- Start
- Dec 2026
- Primary completion
- Mar 2028
01
Overview
Phase 2, open-label trial of NBIP-1435 in congenital adrenal hyperplasia (CAH) (2 arms), sponsored by Neurocrine Biosciences. Primary endpoint: Change From Baseline in Androstenedione (A4) Level at 8 weeks. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
NBIP-1435
03
Conditions
congenital adrenal hyperplasia (CAH)
Beyond the preview
Go deeper on NCT07850739.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07850739.